此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Evaluation of FLT3L Armoured CAR T-cells in HER2 Expressing Malignant Diseases in Adults (ECHIDNA)

2026年11月11日 更新者:Peter MacCallum Cancer Centre, Australia

Evaluation of FLT3L Armoured CAR T-cells in HER2 expressIng Malignant Diseases iN Adults

The goal of this clinical trial is to learn if a novel CAR-T cell therapy, called autologous PMCC-COE-HER2FLT3L CAR-T cells, is safe and effective at treating solid tumours that express high levels of the marker HER-2. Patients who have solid tumours that express the marker HER-2, and who have previously progressed or where unsuitable for current HER-2 targeted medications, will be recruited to the study. The PMCC-COE-HER2FLT3L CAR T-cells will be produced using LV and administered to patients after lymphodepleting conditioning chemotherapy. Patients will be then monitored for any side effects as a result of the CAR-T infusion and will have scans performed to assess how their tumour responds to the therapy.

研究概览

详细说明

This is a phase I dose escalation, open label, single centre study investigating the efficacy and safety of PMCC-COE-HER2FLT3L in patients with relapsed/refractory HER2 expressing malignancies.

Patients who meet all eligibility criteria will be registered on to the study with the intention to undergo leukapheresis for the manufacture of PMCC-COE-HER2FLT3L cells by Cell Therapies Pty, Ltd. In patients with progressing disease or, if symptom control is required, bridging therapy (investigator's choice) may be given during the PMCC-COE-HER2FLT3L manufacturing period (approximately 4-6 weeks).

Once supply of PMCC-COE-HER2FLT3L has been confirmed, patients will receive lymphodepleting chemotherapy with fludarabine (25 mg/m2 intravenous [IV]) and cyclophosphamide (250 mg/m2 IV) daily for 3 consecutive days. At the investigator's discretion, an alternative regimen of bendamustine 90 mg/m2 IV daily for 2 days may be used, or lymphodepleting chemotherapy may be dose-reduced or omitted.

Safety will be assessed by the occurrence of DLTs in the first 28 days, MT, AEs, and SAEs. Dose escalation will occur via an accelerated single patient dose escalation schema. Efficacy will be assessed by RECIST1.1 response criteria, PFS and OS.

研究类型

介入性

注册 (估计的)

12

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

16年 及以上 (孩子、成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Patient (and/or their legal guardian) has provided written informed consent using the ECHIDNA Patient Information and Consent Form (PICF)

  2. Age ≥ 16 years on the day of signing informed consent

  3. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 to 2 (Appendix 6)

  4. Patients should have unresectable, or metastatic disease based on most recent imaging. The following tumour types are eligible for this study:

    1. Patients with histologically documented HER2-positive breast cancer: Tumour must be HER2 in situ hybridisation (ISH)-positive by local testing using current American Society of Clinical Oncology-College of American Pathologists (ASCO-CAP) guidelines for scoring in breast cancer. Patients must have progressed after and/or are not suitable for a trastuzumab-containing treatment and trastuzumab deruxtecan per investigator assessment
    2. Patients with histologically documented gastric/gastroesophageal junction cancer: Tumour must be HER2 IHC 3+ or IHC 2 +/ISH-positive based on local tissue testing results in accordance with ASCO-CAP guidelines for scoring in gastroesophageal adenocarcinoma. Patients must have progressed after at least one prior trastuzumab-containing regimen
    3. Patients with histologically documented colorectal cancer: Tumour must be HER2 IHC 3+ or IHC 2+/ISH-positive based on local tissue testing results in accordance with ASCO-CAP guidelines for scoring in gastroesophageal adenocarcinoma. Patients must have progressed after available therapies including fluoropyrimidine based chemotherapy
    4. Other tumour types: Patients with histologically confirmed biliary tract cancer (including intra- or extrahepatic cholangiocarcinoma and tumours arising in the ampulla of Vater or gallbladder), cervical cancer, endometrial cancer, sarcoma, salivary duct carcinoma, and pancreatic adenocarcinoma. Tumour must be HER2 IHC 3+ or IHC 2+/ISH-positive based on local tissue testing results in accordance with ASCO-CAP guidelines for scoring in gastroesophageal adenocarcinoma. Patients must have progressed following at least one prior systemic treatment and have no satisfactory alternative treatment option as judged by the investigator

    Note: Patients who have had prior treatment with a HER2-targeting CAR T-cell therapies will be potentially eligible, if detectable HER2 expression on malignant cells can be demonstrated (per eligibility criterion #4) and at least 3 months has elapsed between the infusion of any prior cellular therapies and the infusion of the PMCC-COE-HER2FLT3L. If a prior HER2-targeting CAR T-cell therapy has been previously infused, baseline CAR T-cell quantification will be performed on peripheral blood prior to the infusion of PMCC-COE-HER2FLT3L, as outlined in the Schedule of Assessments at the Pre-Leukapheresis timepoint, Section 9.2.1)

  5. Have measurable disease, as defined by RECIST1.1 (Appendix 1)

  6. Have a life expectancy of ≥ 3 months, as judged by the investigator

  7. Adequate haematological function documented within 7 days prior to registration, defined as:

    • Haemoglobin ≥ 80 g/L (peripheral red blood cell transfusion support is allowed)
    • Absolute neutrophil count (ANC) ≥ 1.0 x 109/L (granulocyte-colony stimulating factor [G-CSF] support is allowed, and ANC > 0.5 x 109/L is allowed if neutropenia is due to disease infiltration of bone marrow)
    • Absolute lymphocyte count (ALC) ≥ 0.1 x 109/L
    • Platelets ≥ 50 x 109/L
  8. Adequate cardiac function, defined as:

    • Left ventricular ejection fraction (LVEF) ≥ 50% on echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 90 days prior to registration
    • No suspicion for intercurrent deterioration in left ventricular function as assessed by the investigator
  9. Adequate pulmonary function, defined as:

    • Oxygen saturation measured by pulse oximetry ≥ 90% on room air

  10. Adequate renal function documented within 7 days prior to registration, defined as any one of:

    • A serum creatinine ≤ 1.5 x upper limit of normal (ULN)
    • Creatinine clearance (CrCl) of ≥ 40 mL/min calculated by Cockcroft-Gault formula (Appendix 7)
    • CrCl ≥ 40 mL/min calculated by 24-hour urine collection
    • Glomerular filtration rate (GFR) ≥ 40 mL/min by renal scintigraphy
  11. Adequate hepatic function documented within 7 days prior to registration, defined as all of:

    • Total bilirubin ≤ 1.5 x ULN (or ≤ 3.0 x ULN in patients with Gilbert's syndrome or documented liver involvement)
    • Alanine aminotransferase (ALT) ≤ 3.0 x ULN (or ≤ 5.0 x ULN in patients with documented liver involvement)
    • Aspartate aminotransferase (AST) ≤ 3.0 x ULN (or ≤ 5.0 x ULN in patients with documented liver involvement)
  12. Taking a maximum corticosteroid dose of 20 mg of oral prednisolone or equivalent

  13. Females of childbearing potential (FCBP) and non-sterile male patients (with partners of childbearing potential) must agree to use highly effective methods of contraception from registration on the study to 2 months after the PMCC-COE-HER2FLT3L infusion or until PMCC-COE-HER2FLT3L is no longer present by quantitative PCR on two consecutive tests whichever is later. Effective methods of contraception are:

    • Total abstinence from sexual intercourse when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
    • Female sterilisation (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or bilateral tubal ligation at least 6 weeks prior to registration. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment
    • Male sterilisation (at least 6 months prior to screening), noting that for female patients on the study, the vasectomised male partner should be the sole partner for that patient
    • Use of oral, (oestrogen and progesterone), injected or implanted hormonal methods of contraception or placement of an intrauterine device or intrauterine system, or other forms of hormonal contraception that have comparable efficacy (failure rate < 1%), for example hormone vaginal ring or transdermal hormone contraception. In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months prior to registration
    • Women are considered post-menopausal and not of child-bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age-appropriate history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or tubal ligation at least 6 weeks prior to registration. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment is she considered not of childbearing potential
  14. Females of childbearing potential must have a negative serum beta-human chorionic gonadotropin (β-hCG) pregnancy test within 3 days prior to registration

  15. Sexually active male patients must use a condom during intercourse and must agree to refrain from sperm donation, from registration on the study until 12 months after PMCC-COE-HER2FLT3L infusion

Exclusion Criteria:

  1. Active interstitial lung disease (ILD)/pneumonitis or history of (non-infectious) ILD/pneumonitis within 60 days prior to registration

  2. Uncontrolled pleural effusion(s), ascites or pericardial effusion that requires repeated drainage procedures

  3. Symptomatic, or active central nervous system (CNS) metastases and/or carcinomatous meningitis

    Note 1: Patients with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging, clinically stable, and without requirement of steroid treatment for at least 14 days prior to registration. Anticonvulsant therapy at a stable dose is permitted

    Note 2: Patients with untreated brain metastases not requiring immediate local therapy are eligible provided all CNS lesions are < 2.0 cm in maximal diameter on contrast brain MRI, they are clinically stable, and without requirement of steroid treatment for at least 14 days prior to registration. Anticonvulsant therapy at a stable dose is permitted

    Note 3: Patients with metastases to the midbrain, pons, medulla, or spinal cord are not eligible

  4. Patients with CNS disease who cannot undergo MRI assessment

  5. Patients with brain stem lesions

  6. Major surgery within 4 weeks prior to registration

  7. Receipt of a live, attenuated vaccine (except for COVID-19) within 4 weeks prior the planned commencement of lymphodepleting conditioning

  8. Receipt of any investigational medical product within the last 30 days, or after 5 half-lives (whichever is the shortest) prior to planned leukapheresis

  9. Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure or myocardial infarction within 6 months of screening or class III to IV cardiac disease as defined by the New York Heart Association Functional Classification

  10. Clinically significant neurological disorders (e.g., epilepsy, severe brain injury, dementia, Parkinson's disease, or autoimmune/inflammatory disorders [e.g., Guillain-Barre syndrome, motor neuron disease, chronic inflammatory demyelinating polyneuropathy])

  11. History of other active malignancy, with the exception of:

    • Adequately treated in situ carcinoma of the cervix or breast
    • Adequately treated basal cell carcinoma of skin or localised squamous cell carcinoma of the skin
    • Low grade malignancies that are being observed and do not require treatment (e.g., low risk prostate cancer)
    • Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent and without evidence of recurrence for at least 2 years prior to registration
  12. Active HIV or hepatitis A, B, or C infection

    • Patients who are positive for HIV by enzyme-linked immunosorbent assay or Western Blot, are ineligible
    • Patients who are seropositive for hepatitis C virus (HCV) are eligible if their most recent HCV DNA assay is undetectable (including those that have received curative therapy)
    • Patients who are seropositive for hepatitis B virus (HBV) due to prior infection may be eligible, if their most recent HBV DNA assay is undetectable, and suitable prophylactic therapy is given prior to and after treatment with PMCC-COE-HER2FLT3L (e.g., entecavir)
    • Patients who are seropositive for HBV because of vaccination (surface antibody positivity only) are eligible
  13. Other clinically significant active infection confirmed by clinical evidence, imaging, or positive laboratory tests (e.g., blood cultures, viral DNA/RNA by PCR)

  14. A known history or current autoimmune disease or other diseases resulting in permanent immunosuppression or requiring permanent immunosuppressive therapy (with the exception of corticosteroids up to 20 mg/day of oral prednisolone or equivalent)

  15. Current active graft versus host disease (GVHD) requiring immunosuppression (with the exception of corticosteroids up to 20 mg/day of oral prednisolone or equivalent)

  16. Other significant life-threatening illness, medical condition, or laboratory abnormality that, in the opinion of the investigator, could compromise the patient's safety, impair their ability to receive PMCC-COE-HER2FLT3L, or put the study outcomes at undue risk

  17. Known hypersensitivity to the excipients of PMCC-COE-HER2FLT3L or to any product to be given to the patient as per the study protocol (e.g., tocilizumab and lymphodepleting agents)

  18. Women who are lactating

  19. Presence of any psychological, social, geographical, or other condition for which, in the opinion of the investigator, participation would not be in the best interest of the patient (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:PMCC-COE-HER2FLT3L

Single dose of PMCC-COE-HER2FLT3L CAR-T cells administered following lymphodepleting chemotherapy

PMCC-COE-HER2FLT3L is an autologous CAR T-cell product that combines both HER2 targeting and FLT3L secretion.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Assess the safety of autologous PMCC-COE-HER2FLT3L in patients following lymphodepletion, including identification of the maximum tolerated dose (MTD)
大体时间:From enrolment until 28 days after administration of PMCC-COE-HER2FLT3L CAR-T cells
  • Incidence, nature, and severity of adverse events (AEs) graded according to the Common Toxicity Criteria for Adverse Events Version 6.0 (CTCAE v6.0), and the American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading for cytokine release syndrome (CRS) and Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS), and serious adverse events (SAEs)
  • Incidence, nature, and severity of "moderate" toxicity (MT) events and dose limiting toxicities (DLTs)
From enrolment until 28 days after administration of PMCC-COE-HER2FLT3L CAR-T cells
Assess manufacturing feasibility of PMCC-COE-HER2FLT3L, defined as the percentage of patients in whom a suitable product manufactured, meeting pre-determined criteria for release.
大体时间:From enrolment until administration of the PMCC-COE-HER2FLT3L product

The patient has a suitable product manufactured, meeting pre-determined criteria for release (yes/no).

From enrolment until administration of the PMCC-COE-HER2FLT3L product

次要结果测量

结果测量
措施说明
大体时间
Assess the efficacy of a single dose of PMCC-COE-HER2FLT3L cells as assessed by Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST1.1) by overall response
大体时间:From enrolment to end of follow-up period (52 weeks after administration of PMCC-COE-HER2FLT3L CAR-T cells)

Objective response (defined as: complete response [CR] or partial response [PR]) calculated as the proportion of patients with an objective response (CR or PR) at any stage after PMCC-COE-HER2FLT3L infusion per RECIST1.1

From enrolment to end of follow-up period (52 weeks after administration of PMCC-COE-HER2FLT3L CAR-T cells)
Assess the efficacy of a single dose of PMCC-COE-HER2FLT3L cells as assessed by Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST1.1) by duration of response
大体时间:From enrolment to end of follow-up period (52 weeks after administration of PMCC-COE-HER2FLT3L CAR-T cells)

Duration of response (months) defined as the time from first occurrence of a documented response (CR or PR) to the date of progression per RECIST1.1. Deceased patients without progression will be censored at the date of death

From enrolment to end of follow-up period (52 weeks after administration of PMCC-COE-HER2FLT3L CAR-T cells)
Assess the efficacy of a single dose of PMCC-COE-HER2FLT3L cells as assessed by Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST1.1) by progression free survival (PFS)
大体时间:From enrolment to end of follow-up period (52 weeks after administration of PMCC-COE-HER2FLT3L CAR-T cells)

Progression-free survival (months), measured from the date of PMCC-COE-HER2FLT3L infusion to the date of first progression at any site, as determined by the investigator according to RECIST1.1, or date of death due to any cause. Patients alive and progression free at the last efficacy follow-up visit will be censored at the date of the visit

From enrolment to end of follow-up period (52 weeks after administration of PMCC-COE-HER2FLT3L CAR-T cells)
Determine persistence of PMCC-COE-HER2FLT3L in peripheral blood
大体时间:From enrolment until the end of the follow-up period (52 weeks after administration of PMCC-COE-HER2FLT3L CAR-T cells)

Persistence of PMCC-COE-HER2FLT3L in peripheral blood, as measured by flow cytometry and/or a quantitative polymerase chain reaction (PCR)

From enrolment until the end of the follow-up period (52 weeks after administration of PMCC-COE-HER2FLT3L CAR-T cells)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Katherine Cummins, MBBS (Hons) PhD、Peter MacCallum Cancer Centre, Australia

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月21日

初级完成 (估计的)

2029年10月1日

研究完成 (估计的)

2029年10月1日

研究注册日期

首次提交

2026年9月2日

首先提交符合 QC 标准的

2026年11月11日

首次发布 (实际的)

2026年11月16日

研究记录更新

最后更新发布 (实际的)

2026年11月16日

上次提交的符合 QC 标准的更新

2026年11月11日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅